Progress in Understanding Metabolic Syndrome and Knowledge of Its Compltableex Pathophysiology

Jha, BK; Sherpa, ML; Imran, M; Mohammed, Y; Jha, LA; Paudel, KR; Jha, SK

Progress in Understanding Metabolic Syndrome and Knowledge of Its Compltableex Pathophysiology

Jha, BK Sherpa, ML Imran, M Mohammed, Y Jha, LA Paudel, KR Jha, SK

Permalink

Publisher:: MDPI AG
Publication Type:: Journal Article
Citation:: Diabetology, 4, (2), pp. 134-159

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (2.52 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Jha, BK
dc.contributor.author	Sherpa, ML
dc.contributor.author	Imran, M
dc.contributor.author	Mohammed, Y
dc.contributor.author	Jha, LA
dc.contributor.author	Paudel, KR
dc.contributor.author	Jha, SK
dc.date.accessioned	2023-04-15T12:30:22Z
dc.date.available	2023-04-15T12:30:22Z
dc.identifier.citation	Diabetology, 4, (2), pp. 134-159
dc.identifier.issn	2673-4540
dc.identifier.uri	http://hdl.handle.net/10453/169814
dc.description.abstract	<jats:p>The metabolic syndrome (MetS), first introduced by Haller in 1975, was sometimes also known as insulin resistance syndrome, syndrome X, and plurimetabolic syndrome. In 1989, it was rechristened by Kaplan as the “Deadly Quartet” based on a consolidation of central obesity, impaired glucose tolerance, dyslipidemia, and systemic hypertension. MetS is positively associated with a pro-inflammatory and pro-thrombotic state, attributed to increased pro-thrombotic and inflammatory marker activity. Moreover, MetS is frequently associated with increased atherosclerotic cardiovascular disease, impaired glucose tolerance, hyperuricemia, obstructive sleep apnea, and chronic kidney disease. Despite concerted endeavors worldwide, the complexity of the pathophysiology of metabolic syndrome still needs to be clearly understood. Currently, therapeutic possibilities are confined to individual therapy for hyperglycemia, hypertension, hypertriglyceridemia, hyperuricemia, regular physical exercise, and a restricted diet. In this review, progress regarding the understanding and pathophysiology of MetS; recent emerging technologies, such as metabolomics and proteomics; the relation of MetS with obesity, diabetes, and cardiovascular diseases; and the association of MetS with COVID-19 are discussed.</jats:p>
dc.language	en
dc.publisher	MDPI AG
dc.relation.ispartof	Diabetology
dc.relation.isbasedon	10.3390/diabetology4020015
dc.rights	info:eu-repo/semantics/openAccess
dc.title	Progress in Understanding Metabolic Syndrome and Knowledge of Its Compltableex Pathophysiology
dc.type	Journal Article
utslib.citation.volume	4
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Strength - CFI - Centre for Inflammation
utslib.copyright.status	open_access	*
dc.date.updated	2023-04-15T12:30:20Z
pubs.issue	2
pubs.publication-status	Published online
pubs.volume	4
utslib.citation.issue	2

Abstract:

The metabolic syndrome (MetS), first introduced by Haller in 1975, was sometimes also known as insulin resistance syndrome, syndrome X, and plurimetabolic syndrome. In 1989, it was rechristened by Kaplan as the “Deadly Quartet” based on a consolidation of central obesity, impaired glucose tolerance, dyslipidemia, and systemic hypertension. MetS is positively associated with a pro-inflammatory and pro-thrombotic state, attributed to increased pro-thrombotic and inflammatory marker activity. Moreover, MetS is frequently associated with increased atherosclerotic cardiovascular disease, impaired glucose tolerance, hyperuricemia, obstructive sleep apnea, and chronic kidney disease. Despite concerted endeavors worldwide, the complexity of the pathophysiology of metabolic syndrome still needs to be clearly understood. Currently, therapeutic possibilities are confined to individual therapy for hyperglycemia, hypertension, hypertriglyceridemia, hyperuricemia, regular physical exercise, and a restricted diet. In this review, progress regarding the understanding and pathophysiology of MetS; recent emerging technologies, such as metabolomics and proteomics; the relation of MetS with obesity, diabetes, and cardiovascular diseases; and the association of MetS with COVID-19 are discussed.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/169814